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Preface  
Chromosome mis-segregation generates aneuploid daughter cells, which contain 
an incorrect chromosome number. Although aneuploidy interferes with 
proliferation of untransformed cells, it is also, paradoxically, a hallmark of cancer, 
a disease defined by increased proliferative potential. These contradictory effects 
are also observed in mouse models of chromosome instability (CIN). CIN can 
inhibit and promote tumorigenesis. Recent work has provided insights into the 
cellular consequences of CIN and aneuploidy. Chromosome mis-segregation per 
se can alter the genome in many more ways than causing the gain or loss of 
chromosomes. The long-term effects of aneuploidy are caused by gene-specific 
effects and a stereotypic aneuploidy stress response. Importantly, these recent 
findings provide insights into the role of aneuploidy in tumorigenesis.  
 
 
Introduction 
The term “aneuploidy” was coined by Gunnar Tackholm in 19221. He studied the 
karyotypes of meiotic cells of F1 hybrids from crosses between different rose 
species. He noted that in meioses of a subset of these F1 hybrids “bivalent and 
univalent chromosomes are not a multiple of seven (author’s note: the haploid 
chromosome number of the genus Rosa). In many instances this is also the case 
for their somatic karyotypes. Because it is necessary to coin a term for a 
chromosome number that is not a multiple of the base chromosome number, I 
will call this condition aneuploidy. Henceforth, aneuploidy refers to hyper and 
hypoploid chromosome numbers.”1.  
 
Whereas aneuploidy is a frequent outcome of meioses in progeny of interspecies 
crosses, it rarely arises during the mitotic divisions that form the soma and during 
meiosis of intraspecies crosses. This is because surveillance mechanisms that 
prevent chromosome mis-segregation, such as the spindle assembly checkpoint 
(SAC) (BOX 1), are in place2-6. Although these safeguard mechanisms are well 
characterized, the cellular consequences of their failure and what happens to 
cells in which these safeguard mechanisms failed and that have become 
aneuploid is only beginning to be understood. The reason for why we lack a 
detailed understanding of the consequences of chromosome mis-segregation is 
that studying faulty chromosome segregation and the resultant aneuploidies is 
difficult. Chromosome mis-segregation is a rare event and hence difficult to 
capture. The analysis of the products of chromosome mis-segregation, cells with 
aneuploid genomes, is equally tricky. Studying small changes in gene dosage – 
chromosome gains or losses result in a 50% change in gene expression7-16 – is 
difficult. Dissecting the complex consequences of hundreds if not thousands of 
such small changes in gene expression occurring simultaneously is even more 
challenging. With the development of ever more sophisticated live cell imaging 
tools and quantitative genome-wide methods we are, however, beginning to 
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make headways. We now appreciate that chromosome mis-segregation can 
have a dramatic impact on genome integrity, causing DNA damage and genomic 
rearrangements. We are also making progress towards understanding the impact 
of an unbalanced karyotype on cell and organismal physiology. It has now 
become clear that the phenotypes of aneuploid cells are composites of 
phenotypes caused by specific gene imbalances and general aneuploidy 
associated traits caused by simultaneous changes in gene dosage of many 
genes, which have little effects when varied individually. Advances in 
understanding the immediate and long-term effects of chromosome mis-
segregation are urgently needed. Whole chromosome gains and losses have a 
dramatic impact on human health. They are the leading cause of miscarriages 
and mental retardation in humans and a hallmark of cancer. 
 
In this review, we will first discuss the detrimental effects of chromosome mis-
segregation and aneuploidy on cell physiology. We will describe recent findings 
that show that the process of chromosome mis-segregation has dramatic effects 
on genome integrity causing DNA damage and activation of p53. We will next 
summarize our current understanding of how an altered karyotype affects the 
cell’s proteome and physiological state. We will end with a discussion of links 
between chromosome mis-segregation, aneuploidy and cancer, reviewing recent 
evidence suggesting a causative role for chromosome mis-segregation and 
aneuploidy in tumorigenesis.  
 
Aneuploidy is rare in normal tissues. 
When aneuploidy is present throughout the organism it is known as 
constitutional aneuploidy. Such aneuploidies are caused by chromosome 
segregation errors during germ cell formation, usually during meiosis (reviewed in 
REF17). Somatic aneuploidy is the result of mitotic errors and describes a 
condition in which only a fraction of cells in an organism harbors an abnormal 
karyotype. Most constitutional aneuploidies cause embryonic lethality, the most 
notable exception in humans being Trisomy 21 (Down Syndrome). The 
consequences of high levels of somatic aneuploidy are also severe. Patients with 
the rare human syndrome, mosaic variegated aneuploidy (MVA), which is, 
amongst other mutations, caused by mutations in BUB1B, a gene required for 
accurate chromosome segregation (reviewed in REF5, Box1) exhibit growth 
retardation, microcephaly and childhood cancers18.  
 
Given the profound adverse effects of aneuploidy on human health it is not 
surprising that cells with an unbalanced karyotype are rare. In budding and 
fission yeast, for example, chromosome loss rate is estimated to be between 
1x10-5 and 1x10-4 per generation19-22 (Table 1). Primary and non-transformed 
tissue culture cell lines exhibit a chromosome mis-segregation rate of 
approximately ~2.5x10-2%23 per chromosome. Extending this result to all 
chromosomes suggests a chromosome loss or gain rate of ~1% 23,24 (Table 1). 
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The degree of aneuploidy observed in tissues is in agreement with these mis-
segregation frequencies. Mouse lymphocytes and mouse and human 
keratinocytes exhibit aneuploidy frequencies of around 3%25,26. However, 
mammalian brain and liver were reported to exhibit significantly higher levels of 
aneuploidy. Fluorescent in situ hybridization (FISH) analyses suggested that as 
many as 50% of liver cells in humans are aneuploid27-29; spectral karyotyping 
(SKY)30 or FISH25,30-33 studies reported 20 – 33% of brain cells to be aneuploid. 
However, subsequent single cell sequencing analyses contradicted these 
previous results and revealed that the brain and liver have low levels of 
aneuploidy similar to those seen in other tissues26,34,35 (Table 1). The 
overestimation of aneuploidy by FISH and SKY is likely due to hybridization and 
chromosome spreading artifacts, respectively. Furthermore, even a low 
frequency of artifacts for a single chromosome can lead to a gross overestimation 
of aneuploidy when extrapolated across all chromosomes. 
 
Chromosome segregation defects are more frequent during meiosis and the 
effects on reproductive success significant (reviewed in REF17). In humans, 
approximately 35% of spontaneous abortions, 4% of stillbirths and as many as 
25% of all zygotes are aneuploid17,36,37 (Table 1).  
 
Together, these observations indicate that constitutional and somatic 
aneuploidies are rare but when they occur, their impact on health is dramatic. In 
what follows we will summarize our current understanding of how the immediate 
and long-term effects of chromosome mis-segregation cause decreased fitness, 
disease and even death. 
 
 
Immediate effects of segregation errors 
There are two consequence of chromosomes mis-segregation:  a faulty mitosis 
occurs and the resulting daughter cells are aneuploid. Recent studies indicate 
both outcomes have a dramatic impact on cells.  
 
Chromosome mis-segregation causes DNA damage. 
To understand the immediate consequences of chromosome mis-segregation, 
the frequency of chromosome mis-segregation events was increased by 
interfering with mitotic spindle function38. In such abnormal mitoses, mis-
segregating chromosomes frequently lag behind during anaphase and can 
become entrapped and damaged in the cleavage furrow during cytokinesis 
(Figure 1). The broken chromosomes elicit a DNA damage response. Their repair 
via non-homologous end-joining during the following G1 phase of the cell cycle 
can but may not always lead to translocations and deletions38,39.  
 
Lagging chromosomes sometimes also do not catch up with the other 
chromosomes in time to be incorporated into the reforming nucleus. Such 
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chromosomes then form their own micronuclei40-43 (Figure 1). These micronuclei 
are not just miniature nuclei as they are not fully functional39 .DNA replication 
proceeds slowly in micronuclei39,43. Given the importance of a functional nuclear 
envelope for efficient DNA replication44, defects in nuclear import39-41 or 
irreversible nuclear envelope collapse45 could be responsible for this inability of 
micronuclei to properly replicate their DNA (Figure 1). The consequences on 
DNA integrity are dramatic: DNA damage levels are high in micronuclei and their 
repair leads to extensive DNA rearrangements39,46, as elegantly demonstrated by 
combining life cell imaging and single cell sequencing techniques46. The complex 
chromosomal rearrangements that form in micronuclei are reminiscent of 
chromothripsis47,48,49, which has been observed in approximately 3% of cancers 
and is prevalent in osteosarcomas (35%) and aggressive neuroblastomas 
(18%)48,49. Chromotripsis has also been observed in some human congenital 
diseases50 where, as in cancer, it might provide the fuel for rapid genome 
evolution. 
 
Chromosome mis-segregation causes p53 activation 
Errors in chromosome segregation result in p53 activation. Increased levels of 
p53 and expression of p53 responsive genes were detected following 
chromosome mis-segregation that resulted in a G1 arrest51. Consistent with a 
role of p53 in causing the arrest, G1 arrest was alleviated by p53 inactivation. 
Moreover, p53 also limits the proliferation of cells experiencing high levels of 
chromosome mis-segregation in the embryo. Mutant mice lacking the gene 
encoding the spindle assembly checkpoint component Mad2 die at embryonic 
day 6.552. Similarly, MAD2-/- mouse blastocysts die in culture within 5 days but 
when p53 is deleted blastocysts remain viable for many weeks53. Thus, p53 plays 
a central role in preventing cell cycle progression following chromosome mis-
segregation.  
 
Which aspect of chromosome mis-segregation causes p53 activation remains a 
key unanswered question, for which consensus hasn’t been reached yet. One 
study 38 has suggested that DNA damage during cytokinesis causes p53 
activation (Figure 2a). However, in another study51, DNA damage following 
chromosome mis-segregation was not detected and it was proposed that 
aneuploidy per se activates p53 (Figure 2b). Similarly, another group54 observed 
p53 activation in SAC-deficient MEFs but not DNA damage. Instead, this group 
reported that reactive oxygen species (ROS) were elevated following 
chromosome mis-segregation.  High levels of ROS caused activation of the DNA 
damage checkpoint kinase ATM and of p53 (Figure 2c). It is noteworthy that 
increased levels of ROS have also been observed in aneuploid budding yeast 
strains11.  
 
What could be the reason for these different results? DNA damage occurring 
during chromosome mis-segregation is likely to be transient and could have been 
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missed in some studies. Differences in experimental procedure could also 
determine whether or not p53 is activated. Some approaches used to generate 
aneuploid cells involve arresting cells in pro-metaphase for prolonged periods of 
time. Arresting cells in pro-metaphase for more than 90 minutes causes a p53-
dependent G1 arrest when cells are released from the cell cycle block 
irrespective of whether or not chromosomes had been mis-segregated55. The 
mechanisms whereby prometaphase length causes p53 activation are not 
understood, but multiple events could contribute (Figure 2d). Prolonged 
prometaphase arrest causes apoptosis and hence a DNA damage response56, 
telomere uncapping57, p38 activation55 and a decrease in Mdm2 levels, which 
targets p53 for degradation58-60. All these events could lead to p53 activation. 
 
In summary, which aspects of chromosome mis-segregation – there could be 
multiple - activate p53 remains to be clearly defined. Interestingly, p53 activation 
has not been observed in cells with constitutional aneuploidies61, which suggests 
that p53 activation is an immediate consequence of chromosome mis-
segregation and is attenuated in cells with constitutional aneuploidies or is only 
elicited by specific aneuploid karyotypes. 
 
Long-term effects of an altered karyotype 
 
Changes in chromosome composition cause a multitude of phenotypes and have 
long-term effects. The reason is that changes in the copy number of genes 
located on autosomes largely, although not universally, result in a corresponding 
change in gene expression. A systematic analysis of budding yeast strains 
carrying single additional chromosomes showed that approximately 80% of 
genes that are present in an additional copy are expressed at an accordingly 
increased level11. The genes that do not show increased expression 
predominantly encode proteins that function in multi protein complexes such as 
the ribosome11. Similar observations were made in fission yeast, Arabidopsis 
thaliana, and mammalian cells10,12,13,15,16,62-66 but the principle that gene copy 
number determines abundance of gene product may not be universal. Dosage-
compensation mechanisms such as those described for sex chromosomes, 
may exist for autosomes in Drosophila melanogaster and in some plants67-71.  
 
Which aspects of gaining and losing whole chromosomes cause the phenotypes 
observed in aneuploid cells and organisms? Although studies in budding yeast 
have shown that the presence of 5 additional centromeric plasmids interferes 
with microtubule – kinetochore attachment72, gaining or losing DNA per se is 
generally not considered as the major cause for phenotypic changes associated 
with aneuploidy. This was demonstrated by introducing large amounts of 
mammalian DNA into budding yeast cells. Little or not proteins are synthesized in 
budding yeast from this foreign DNA because, even if the mammalian genes 
were transcribed, the yeast splicing machinery cannot splice mammalian 
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mRNAs. Introducing mammalian DNA in the form of yeast artificial chromosomes 
(YACs) as large as approximately 13% of the yeast genome (1.6Mb) has little 
impact on the fitness of yeast strains14. This observation, together with the fact 
that autosomal dosage-compensation mechanisms are not in place indicates that 
the phenotypes that are observed in aneuploid yeast cells are caused by 
changes in the expression of genes located on the aneuploid chromosomes.  
 
The finding that in budding yeast all aneuploidy-associated phenotypes analyzed 
to date are attenuated by increased ploidy14,73 further indicates that it is relative 
levels of gene dosage that are mainly responsible for the phenotypes associated 
with an altered karyotype. Phenotypes caused by the gain of single 
chromosomes are drastically attenuated in diploid yeast cells compared to 
haploid yeast cells14,73. Thus, polyploidy represents an aneuploidy-tolerating 
condition. This is illustrated by the observation that tetraploid yeast strains exhibit 
a 200-fold increase in chromosome loss compared to diploid yeast strains, yet 
proliferation is only mildly impaired22. In cancers too, an increase in genome-wide 
ploidy (many cancers are tetraploid) probably protects cancer cells from the 
adverse effects of aneuploidy allowing them to take advantage of potential 
beneficial traits conferred by altered dosage of specific oncogenic drivers. 
 
In what follows we will provide examples for how changes in copy number of 
specific genes (gene specific effects) interfere with development and cause 
diseases. We will then describe how simultaneously changing the copy number 
of many genes that on their own have little impact on cellular functions cause a 
generic set of phenotypes known as the aneuploidy associated stresses. 
 
Gene specific effects of aneuploidy 
Changes in gene copy number have been linked to many diseases (reviewed in 
ref74,75). For example, duplication of the APP gene (encoding amyloid beta 
precursor protein) has been implicated in early onset Alzheimer's disease76, 
deletion of one copy of PMP22 (the gene encoding peripheral myelin protein 22) 
is the cause of Charcot-Marie-Tooth 1A neuropathy77. While examples of 
changes in gene copy number causing developmental abnormalities and 
diseases are numerous, dramatic effects of gaining or losing single genes on 
cellular fitness are less common. The best-known example is the β-tubulin gene 
in Saccharomyces cerevisiae. An additional copy of this gene is lethal78. Only a 
handful of other genes have been shown to reduce fitness when present at an 
additional copy under standard growth conditions79. Similarly, only few genes 
were found to reduce fitness when present at one copy instead of two. In budding 
yeast only 184 genes (3% of the yeast genome) are haploinsufficient for growth 
under optimal growth conditions80. This number is higher in fission yeast81 (455 
genes), most likely because fission yeast predominantly propagates as a haploid 
whereas budding yeast as diploid, which presumably causes haploinsufficiency 
to be under strong negative selection81. 
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Understanding how changes in gene dosage of individual genes impact 
development and organismal functions will be important for developing strategies 
to improve the lives of individuals with Down Syndrome. Two recent studies 
suggest that some of the defects caused by an additional copy of chromosome 
21 are reversible. It was found that the cognitive deficiencies in mouse models of 
Down Syndrome can be ameliorated by a Hedgehog agonist therapy82. Silencing 
one copy of chromosome 21 by targeting the X chromosome inactivating Xist 
RNA to one of the three copies of this chromosome greatly improved proliferation 
and neural rosette formation in pluripotent Down Syndrome stem cells83. These 
findings open potential new avenues for the development of therapies for the 
treatment of Down Syndrome.  
 
Aneuploidy-associated stresses  
A 50% change in expression of the majority of genes individually has little if any 
impact on cellular fitness. In contrast, the same change in dosage of many such 
genes simultaneously contributes to the decrease in fitness of cells with 
unbalanced karyotypes and is responsible for traits shared by cells with different 
aneuploidies84 (Figure 3).  We refer to these general traits as the aneuploidy-
associated stresses. Thus far they have only been studied in cellular models of 
aneuploidy, but they probably contribute to the myriad of phenotypes observed in 
aneuploid organisms.  
 
Transcriptional and post-transcriptional responses to aneuploidy. 
Studies of aneuploid budding yeast, fission yeast, and plants, as well as 
aneuploid primary, untransformed mouse and human cells have revealed a 
conserved gene expression response to the aneuploid state14,85-87 (Figure 3). 
Transcripts associated with cell growth, proliferation, and nucleic acid metabolism 
are down-regulated, while transcripts associated with stress and membranes 
functions are up-regulated. These transcriptional alterations are reminiscent of 
the environmental stress response (ESR) first described in budding yeast88,89 
(Figure 3). The ESR is triggered by several stresses and/or slowed growth, and 
the gene expression pattern commonly observed in aneuploid cells is likely the 
result of cellular stress as well as a reflection of the sluggish proliferation of 
aneuploid cells85,87.	  
 	  
In cancers, some transcripts have been found to be more abundant in cancers 
with a high degree of aneuploidy. A gene expression signature derived from this 
study (known as “CIN70”) had been proposed to function as a marker of 
chromosomal instability in cancer. However, subsequent research has 
demonstrated that CIN70 more accurately reflects the proliferation rate of tumors, 
rather than intrinsic CIN91,92. A comparison of high-CIN and low-CIN cancer cell 
lines identified a set of transcriptional changes distinct from CIN70 but similar to 
the ESR observed in primary aneuploid cells. Interestingly, an ESR was not 
	   9	  
observed when comparing the transcriptomes of highly aneuploid breast tumors 
to near-diploid breast tumors. These findings led to the proposal that two types of 
aneuploidy exist in cancers: 1) continuously changing karyotypes that, like 
aneuploidies in primary cells, have a negative impact on cellular fitness and 2) 
selected, stable aneuploid karyotypes that have evolved to support maximal 
proliferation and in which the stresses caused by aneuploid karyotypes are 
suppressed. It is important to note that the gene expression changes caused by 
CIN in cancer and by aneuploidy in primary cells are related but not identical. For 
instance, genes annotated to the mitotic cell cycle are very strongly down-
regulated in trisomic fibroblasts, while in high-CIN cancer cell lines, cell cycle 
genes are moderately down-regulated but RNA metabolism genes are strongly 
suppressed.  The cause of these differences is at present unknown.	  
 
Recently, an additional gene expression signature shared among aneuploid 
budding yeast strains was identified11. This signature, named the aneuploidy-
associated protein signature (APS), is characterized by the up-regulation of 
proteins but not transcripts of genes involved in oxidative stress response. The 
strength of the APS correlates with the degree of aneuploidy, suggesting that the 
degree of karyotype imbalance cause an increase in ROS. Which aspect of the 
aneuploid condition is responsible for elevated ROS remains to be determined. 
However, hyper-activation of the proteasome, through inactivation of the 
proteasome-associated deubiquitinating enzyme Ubp6 suppresses the APS11, 
raising the interesting possibility that proteotoxicity, a hallmark of the aneuploid 
state to be discussed next, contributes to the APS (Figure 3).  
 
Aneuploidy causes proteotoxic stress 
In healthy cells, a complex regulatory network maintains cellular protein 
homeostasis (proteostasis) by ensuring that proteins are present only in their fully 
active form and at appropriate levels93,94. Chaperone-mediated folding pathways 
facilitate the folding of proteins; protein degradation pathways - autophagy and 
the ubiquitin proteasome system (Box 2) - ensure that mis-folded proteins are 
eliminated (reviewed in REF95-99). When these systems become limiting or are 
impaired, unfolded and misfolded proteins accumulate resulting in proteotoxic 
stress (Figure 4). This stress is met by a multi-pronged response aimed at 
increasing the protein quality control capacity of the cell.  
 
Aneuploidy impacts all protein quality control pathways in the cell. Analysis of 
budding yeast strains carrying single additional chromosomes (disomic yeast 
strains) showed that at least one chaperone, the chaperone Hsp90 (reviewed in 
REF100) is limiting in several different disomic yeast strains73. Aneuploid 
immortalized and tumorigenic human cells101 are also defective in HSP90-
mediated protein folding. Reduced protein folding capacity was suggested to be 
caused by a reduced ability to activate a HSF1-induced heat shock response101. 
On the other hand, it was found that basal levels of expression of the HSF1 
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target HSP72 were increased in aneuploid MEFs61. Primary mouse cells may 
respond differently to folding stress than immortalized and cancerous human cell 
lines. Despite these differences, all types of mammalian cell lines carrying one or 
two additional chromosomes analyzed to date are more sensitive to the HSP90 
inhibitor 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)61,101 than euploid 
cells, indicating that Hsp90 is limiting in several aneuploid cells. 
 
Aberrant karyotypes also impact protein degradation pathways, including 
ubiquitin-mediated proteasomal degradation of short-lived proteins and 
autophagy-mediated removal of protein aggregates. Some disomic budding yeast 
strains exhibit sensitivity to the proteasome inhibitor MG13214. Furthermore, 
hyperactivation of proteasomal degradation by deleting the proteasome-
associated deubiquitinating enzyme UBP6 attenuates the aneuploidy induced 
changes in cellular protein composition and improves their fitness11,63. Unlike 
some disomic budding yeast strains, mammalian aneuploid cells do not exhibit 
increases sensitivity to proteasome inhibitors61.  Recent studies indicate that 
proteasome-mediated degradation is increased in aneuploid mammalian cells 101, 
suggesting that proteasome activity is up-regulated in cells with abnormal 
karyotypes101 . Autophagy on the other hand appears to be insufficient in 
aneuploid mammalian cells. Trisomic MEFs and aneuploid human cells exhibit 
increased sensitivity to the lysosome inhibitor chloroquine10,61. Furthermore, the 
gene expression signature of aneuploid human cells is similar to that of cells in 
which lysosomal degradation is inhibited87. Our unpublished data indicate that 
autophagosomes accumulate within lysosomes without evidence of lysosome 
mal-function (SS and AA, unpublished results). It thus appears that autophagy is 
a major route of clearance of mis-folded proteins in aneuploid mammalian cells.  
 
Why is proteotoxicity a universal feature of aneuploid cells? The comparison of 
haploid yeast strains carrying an additional chromosome (disomic strain) with 
diploid yeast strains carrying an extra copy of the same chromosome (trisomic 
strain) provided insight into this question. All phenotypes indicative of proteotoxic 
stress are greatly reduced in trisomes compared to disomes suggesting that 
changes in the relative ratio of proteins are a major source of proteotoxicity in 
aneuploid cells. In haploid cells an extra copy of a gene leads to a doubling of 
gene expression. In diploid cells the relative increase or decrease in expression 
is only 50%. While this difference may be of little consequence for proteins that 
fold spontaneously, it has profound consequences for proteins that require 
chaperones to reach their native conformation. Many protein complex subunits 
are unstable unless bound to their partners, and will often bind to chaperones to 
remain soluble until they associate with their binding partners102. Thus, in 
aneuploid cells every single subunit produced from the additional gene copy will 
require the continuous engagement of chaperones to remain in a soluble state 
and will be need to be eventually degraded when a binding partner cannot be 
found. This latter point is illustrated by the analysis of the proteome of aneuploid 
	   11	  
cells. In disomic budding yeast strains approximately 20 percent of proteins do 
not exhibit increased expression when gene dosage is doubled even though 
transcript levels are up-regulated according to gene copy number13,63. The vast 
majority of proteins whose expression does not scale with gene number are 
subunits of multi-protein complexes10,11,14,63. The ribosome is especially worth 
mentioning in this context. Increasing the copy number of ribosomal genes does 
not lead to a corresponding increase in protein levels11. Given that ribosomal 
proteins constitute about 20% of total protein in yeast 
(http://www.proteomaps.net) eliminating ribosomal subunits produced from 
excess gene copies alone could place a burden on the cell’s protein quality 
control pathways.  
 
At first glance it may seem surprising that changing the expression of genes by 
50 percent challenges the cell’s protein quality control pathways. Granted, 
gaining or losing whole chromosomes causes changes in the expression of 
hundreds sometimes thousands of genes but why does the cell not simply 
continuously increase protein quality control activity as occurs during heat shock? 
A recently discovered feature of gene expression control, that is coordinate 
expression of genes that function in complexes, could explain the inability of cells 
to adapt to the aneuploid state. It was shown that expression of subunits that 
assemble into a complex is coordinated103. This indicates that rather than 
maintaining a large protein quality control reservoir to keep a large pool of 
unassembled protein complex subunits in a soluble state, cells have evolved to 
minimize the need for protein quality control pathways to assemble complexes. 
When subunits of complexes are continuously produced in the incorrect 
stoichiometries as occurs in aneuploid cells the protein quality control pathways 
of the cells are challenged, and proteotoxic stress ensues.  
 
Aneuploidy inhibits cell proliferation. 
Decreased proliferation is another characteristic of aneuploid 
cells10,13,14,16,51,54,104-107. Aneuploid fission yeast strains derived as progeny from 
triploid meioses delay in G1104. Haploid budding yeast strains disomic for one or 
two chromosomes or harboring complex aneuploidies proliferate slowly and 
many such strains also show a G1 delay14,106.  
 
Chromosome mis-segregation and aneuploidy also interfere with proliferation in 
mammalian cells. MEFs harboring hypomorphic mutations in the SAC gene 
BUBR1107, or carry mutations in the SAC target Cdc20 that render it insensitive to 
checkpoint regulation54, or that interfere with the chromosome segregation 
process (through depletion of the kinesin MCAK or upon Monastrol wash-out 
exhibit proliferation defects. Some mutations that increase chromosome mis-
segregation, for example cells heterozygous for a deletion in CENP-E108, 
Rae1109, or Bub3109, have not been reported to decrease cell proliferation. This 
could be due to the fact that only a small fraction of cells in the population mis-
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segregate chromosomes causing the ensuing proliferation defect to be subtle 
and thus missed. Proliferation defects are also observed in cells harboring 
constitutive aneuploidies. Trisomy 21 human fibroblasts or MEFs trisomic for 
chromosome 1, 13, 16 or 19 divide more slowly although a specific cell cycle 
delay could not be identified16. However, other trisomic human cells show a G1 
delay10 indicating that, as in yeast, G1 delay is a common occurrence in 
aneuploid mammalian cells. 
 
An important question regarding the proliferation defects of aneuploid cells is 
whether they are the consequence of copy number changes of a few especially 
harmful genes, or whether they are brought about by copy number alterations of 
many genes that cause no growth defect when varied individually. As with most if 
not all aneuploidy-associate phenotypes the answer is likely to be that both 
contribute. For example, a single additional copy of chromosome VI causes 
lethality in haploid budding yeast cells because a single additional copy of the β-
tubulin encoding gene TUB2 is lethal78. Such cases are however rare, at least in 
budding yeast. A genome-wide study in budding yeast determined the upper 
copy number limit of every gene in the budding yeast genome and identified 55 
genes that are not tolerated at more than 5 copies per haploid genome110. 
Changes in copy number of these most dosage sensitive genes are however 
insufficient to drive the proliferation defects of aneuploid cells84. Introducing an 
additional copy of these dosage sensitive genes into yeast strains did not 
recapitulate the growth defects of yeast strains carrying an additional copy of the 
chromosome the genes are located on.  This finding indicates that the 
proliferation defects of aneuploid budding yeast cells are largely caused by 
simultaneous gene copy number changes that independently are benign at least 
under standard growth conditions. 
 
So if it is not only individual genes that at altered dosage impair proliferation in 
aneuploid cells, which other aspects of the aneuploid condition do? Aneuploidy-
induced proteotoxicity appears to contribute to the proliferation defect of 
aneuploid cells. In budding yeast increasing protein quality control not only 
improves protein homeostasis but also cellular fitness. Deleting UBP6 improves 
proliferation in 11 out of 13 disomic yeast strains under conditions of heat stress 
(growth at 37°C)11. In mammalian cells, increased chaperone expression also 
improves fitness. Overexpression of the heat shock transcription factor HSF1 not 
only rescues the folding defect of human aneuploid cells but also their 
proliferation defect101. Although other aspects of HSF1 biology that are beyond its 
role in protein folding might contribute to improved proliferation of aneuploid cells 
upon HSF1 overexpression, this remarkable finding points to a link between 
aneuploidy-induced proteotoxicity and proliferation defects101. Whether other 
aneuploidy-associated stresses contribute to the reduced proliferative abilities of 
aneuploid cells remains to be determined. 
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Aneuploidy in cancer 
90% of solid tumors and 50% of blood cancers are aneuploid111,112. Whether and 
how aneuploidy promotes tumorigenesis has been an active area of research 
and discussion. The realization that mutations in genes regulating chromosome 
segregation are rare in cancers113-115  together with the observation that 
aneuploidy inhibits proliferation, suggests that aneuploidy is a by-product of 
tumorigenesis that interferes with the process rather than causes it. Indeed, loss 
of tumor suppressors has been shown to cause chromosome instability. RB 
inactivation not only deregulates the G1 – S phase transition but also 
compromises centromere function, which leads to chromosome instability and 
hence aneuploidy116,117. Loss of function mutations in APC cause deregulation of 
the Wnt pathway and decrease chromosome segregation fidelity118.  
 
While aneuploidy can be a byproduct of oncogenic transformation there is 
mounting evidence that aneuploidy can promote tumorigenesis. The analysis of 
cancer genomes indicates that loss of tumor suppressor genes and gain of 
oncogenes drive karyotype changes such as whole or partial chromosome gains 
and losses creating the clonal aneuploid karyotypes characteristic for a specific 
cancer119. However, the analysis of specific aneuploid karyotypes and mouse 
models of CIN revealed that aneuploidy can both promote and inhibit 
tumorigenesis. Mice trisomic for part of chromosome 16 are resistant to ApcMin 
induced colon cancer120. Individuals trisomic for chromosome 21 are less likely to 
develop solid tumors compared to the euploid population121. This tumor 
protective function of trisomy 21 has been attributed to the triplication of the 
DSCR1 gene122. Trisomy 8, on the other hand, appears to promote hematopoietic 
malignancies. 25% of chronic myeloid leukemias (CML), 10–15% of acute 
myeloid leukemias (AML) and 5% of acute lymphoblastic leukemias (ALL) harbor 
an additional copy of chromosome 8123. MYC, a key driver of hematopoietic 
malignancies, is located on chromosome 8 and could be the reason for the 
prevalence of additional copies of chromosome 8 in blood cancers124. 
 
Studies of mouse models of chromosomal instability (Supplementary Table 1), 
the condition that spawns aneuploid karyotypes, too show that akin to other 
forms of genomic instability such as reduction of telomerase activity125 126, CIN 
can promote and inhibit tumorigenesis. A prime example for this dual role of CIN 
in tumorigenesis is the motor protein Cenp-E108. Animals heterozygous for a 
CENP-E deletion harbor increased levels of aneuploidy108 and are significantly 
less likely to develop spontaneous liver tumors and 7,12-
dimethylbenz(a)anthracene (DMBA)-induced tumors108 (see also Supplementary 
Table 1). However, the same animals exhibit an increase in the incidence of 
spleen lymphomas and lung adenomas108. Many other mouse models of CIN 
have been described to promote or inhibit tumorigenesis in a manner that 
depends on the cell type and genetic background in which the abnormal 
karyotype arises. They are summarized in Supplementary Table 1.  
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Recent studies revealed a perhaps general principle whereby aneuploidy can 
promote tumorigenesis127. In a K-RAS-driven model of lung cancer, continuous 
K-RAS expression is required for tumor maintenance. Upon repression of K-RAS 
tumors regress. When chromosome mis-segregation is induced in K-RAS driven 
tumors through the overexpression of the SAC factor Mad2, the disease relapsed 
quickly. This finding suggests that the karyotype heterogeneity created by 
increased CIN facilitates the emergence of K-RAS independent tumors127. 
 
While increased karyotypic instability can facilitate the evolution of advantageous 
karyotypes, it of course is much more likely to generate disadvantageous ones. A 
recent study128 illustrates this double edged nature of CIN. Mice lacking one copy 
of CENP-E exhibit an increase incidence of spleen and lung tumors. Increasing 
chromosome mis-segregation in these mice by interfering with spindle assembly 
checkpoint function decreased tumor formation by increasing cell death128. These 
findings indicate that low rates of chromosome mis-segregation can promote 
tumorigenesis by increasing the likelihood of generating a tumor-promoting 
karyotype. However when chromosome mis-segregation rates become too high, 
tumor cells cannot “hold on” to such tumorigenesis-promoting karyotypes. 
Instead cells with inviable karyotypes are continuously generated leading to cell 
death and hence tumor suppression.  
 
Conclusions and future directions  
Research over the last 5 years has provided significant insights into the 
immediate and long-term consequences of chromosome mis-segregation and 
has provided concrete hypotheses as to how CIN and aneuploidy could promote 
tumorigenesis. Chromosome mis-segregation can lead to structural alterations of 
chromosomes. These alterations and the genomic instability that arises from the 
aneuploid state per se129,130 are likely drivers of tumor evolution. We now also 
understand that aneuploid karyotypes negatively impact cellular fitness but rare 
favorable variants can provide a survival advantage as has been seen in 
microbial evolution studies131-133.  
 
Understanding how certain karyotypes promote specific aspects of tumorigenesis 
will be important next steps in understanding the role of aneuploidy in 
tumorigenesis. It should also be determined whether the gene-specific 
phenotypes and general stresses caused by the aneuploid state can be exploited 
in cancer therapy. Synthetic negative interactions between proteotoxic and 
energy-stress inducing compounds and aneuploidy have been described61. 
Strategies that first select for a specific karyotype to then eliminate it have been 
reported recently in inhibiting the growth of aneuploid fungal pathogens and 
several central nervous system cancer cell lines 134 Aneuploidy is a hallmark of 
cancer yet is rare in normal tissues. Compounds that target the aneuploid state 
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therefore have ideal therapeutic properties: broad spectrum efficacy and high 
specificity. A large-scale effort is now required to identify such compounds.  
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Box 1: Mechanisms that prevent chromosome mis-segregation.  
The process of chromosome segregation is tightly controlled by the spindle 
assembly checkpoint (SAC, also known as the mitotic checkpoint), an 
evolutionary conserved surveillance mechanism that prevents the mis-
segregation of chromosomes5,135 (see the figure). When the sister kinetochores 
attach to microtubules emanating from only one spindle pole (syntelic 
attachment) or only one of the two sister kinetochores attaches to microtubules 
(monotelic attachment) the SAC is activated and inhibits anaphase onset. When 
all kinetochores have attached to microtubules emanating from opposite poles, 
known as amphitelic attachment or bi-orientation the SAC is silenced and 
anaphase commences (see the figure). Syntelic and monotelic microtubule – 
kinetochore attachments recruit core components of the SAC - MAD1, MAD2, 
BUB3, BUBR1 and the checkpoint kinases AURORA B, BUB1 and MPS1. The 
recruitment of these proteins catalyzes the inhibition of the anaphase-promoting 
complex/cyclosome (APC/CCDC20), an E3 ubiquitin ligase that triggers the 
metaphase to anaphase transition (left panels).  
 
Inhibition of APC/CCDC20 is brought about by the incorporation of the APC/C 
activator CDC20 into the mitotic checkpoint complex (MCC), composed of the 
checkpoint proteins MAD2, BUBR1, BUB3, and CDC20 itself. Once all 
kinetochores achieve amphitelic attachment, the SAC is turned off and 
APC/CCDC20 is activated. APC/CCDC20 then targets SECURIN and CYCLIN B for 
degradation by the 26S proteasome.  This leads to loss of sister chromatid 
cohesion and inactivation of CDK1. These events trigger chromosome 
segregation and mitotic exit, respectively (right panels).  
 
Kinetochores that attach to microtubules that emanate from both spindle poles 
are referred to as exhibiting merotelic attachments and are thought to be the 
major cause of aneuploidy in mammalian cells136. These types of kinetochore – 
microtubule attachments are not recognized by the SAC but instead are 
converted into amphitelic attachments through the action of Aurora B and Mps1 
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kinases. The protein kinases convert merotelic attachments into amphitelic ones 
by destabilizing microtubule kinetochore interactions by phosphorylating outer 
kinetochore components. 
 
Box 2: Cellular protein quality control 
Proteins must adopt a defined three-dimensional structure to be functional. A 
complex network of chaperone systems ensures that polypeptides reach their 
functional conformation. However, even after adopting the folded conformation, 
proteins are at risk of unfolding, because the energy barrier between folded and 
unfolded or mis-folded conformations is not insurmountable. Stress conditions or 
intrinsic instability can further contribute to protein mis-folding.  
 
Mis-folded proteins either reengage chaperones to reattempt correct folding or 
are degraded. Degradation is mediated by ubiquitin-mediated proteasomal 
degradation. The concerted functions of E1, E2 and E3 enzymes brings about 
the ubiquitination of the misfolded protein thereby targeting the mis-folded protein 
for degradation by the proteasome98,99 (see the figure, top).  
 
When folding load exceeds chaperone capacity and/or when the ubiquitin–
proteasome system is compromised, mis-folded/unfolded proteins can form 
aggregates. Such aggregates are cleared by autophagy.  Deubiquitinating 
enzymes (DUBs) and E3 ubiquitin ligases remodel ubiquitin chains that are then 
able to bind ubiquitin receptors, such as p62/SQSTM1 and NBR198. 
Autophagosomal membranes then form around the ubiquitianted aggregates98. 
Once encapsulated into autophagosomes, protein aggregates are delivered to 
lysosomes where they are degraded (see the figure, bottom).  
 
Figure legends: 
Figure 1: Lagging chromosomes experience DNA damage 
(a) Accurate chromosome segregation leads to the equal partitioning of the 
genome and the generation of two euploid daughter cells, with a balanced, 
diploid karyotype (depicted as 2N in figure).  
(b) Merotely, defined as a kinetochore that attaches to microtubules 
emanating from both spindle poles, can cause chromosomes to lag behind 
in the spindle midzone during anaphase. Such lagging chromosomes can 
have multiple fates. They can be trapped in the cytokinetic furrow and 
break during cytokinesis (top). They can form their own micronucleus that 
is either accurately segregated (middle) or mis-segregated (bottom). 
Irrespective of how micronuclei are segregated their DNA is poorly 
replicated and experiences significant damage in the subsequent cell 
cycle. 2N+x and 2N-x indicate aneuploid karyotypes in which an undefined 
number of chromosome(s) has been gained (+x) or lost (-x).  
 
 
	   17	  
Figure 2: Multiple mechanisms could be responsible for p53 activation 
following chromosome mis-segregation. 
(a) Chromosomes trapped in the cytokinetic furrow are damaged and cause 
activation of the DNA damage checkpoint pathway and hence p53 
activation38. 2N+x and 2N-x indicate aneuploid karyotypes in which an 
undefined number of chromosome(s) has been gained (+x) or lost (-x).  
(b) Aneuploidy per se causes activation of p53 through p38 by an unknown 
mechanism51. 
(c) Aneuploidy causes metabolic changes that lead to an increase in ROS. 
ROS activates the DNA damage checkpoint kinase ATM which in turn 
activates p5354.  
(d) Prolonged mitotic arrest causes p53 activation. When cells are arrested in 
pro-metaphase for more than 1.5 hours, cells activate p53 upon release 
from the pro-metaphase block55. How p53 activation occurs is not 
understood but could result from, partial activation of apoptosis, telomere 
uncapping (through the loss of telomere capping protein TRF2), p38 
activation or Mdm2 down-regulation that occur during prolonged mitotic 
arrest57. 
 
Figure 3:  The aneuploidy-associated stresses 
The aneuploid state elicits a number of cellular responses. Proteotoxic and 
energy stress have been proposed to cause activation of the APS, which involves 
the up-regulation of proteins required for oxidative stress response and energy 
homeostasis. Aneuploidy also leads to slowed proliferation and an associated 
environmental stress response (ESR)-like response, in which stress response 
genes are up-regulated and cell proliferation genes are down-regulated. 
Aneuploid cells also activate p53, leading to impaired proliferation or apoptosis. 
This could be the result of genomic instability and activation of the DNA damage 
kinase ATM, activation of the stress kinase p38, prolonged cell cycle arrest, 
altered energy homeostasis or a combination thereof. 
 
Figure 4: Protein quality control is limiting in aneuploid cells.  
(a) In euploid cells protein quality-control and feedback mechanisms ensure 
that equal amounts of protein complex subunits are produced. 
Chaperones promote protein folding and maintain complex subunits that 
lack a binding partner in a soluble state. Eventually, excess and mis-folded 
subunits are degraded by the proteasome.  
(b) In aneuploid cells protein stoichiometries of protein complex subunits are 
altered. Every subunit encoded by an unbalanced chromosome that 
functions in a protein complex lacks its binding partner(s) and must rely on 
cellular chaperones to remain soluble and, if no binding partner is found, 
on cellular proteases for its eventual degradation. This can lead to an 
increased burden on the cell’s protein quality-control systems. 
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Table 1 – Frequency of aneuploidy 
 Method of 
detection 
Incidence of aneuploidy 
or chromosome mis-
segregation rate 
Refs. 
Mitotic division    
Saccharomyces cerevisiae Plasmid and 
YAC loss  
0.001-0.01% 19-22 
Schizzosaccharomyces 
pombe 
Minichromosome 
loss 1x10-4 
137 
Human tissue culture cells FISH ~1% 23,24 
Mouse keratinocytes  Single-cell 
sequencing 
2.7% 26 
Human keratinocytes Single-cell 
sequencing 
0% 26 
Human and mouse brain Single-cell 
sequencing 
3-5% 26,34 
Human and mouse liver Single-cell 
sequencing 
~5% 26 
Human tissue culture cells 
displaying CIN 
FISH 20-100% 23 
Cancer SKY >85% 6,138 
Meiotic divisions    
Saccharomyces cerevisiae 
YAC mis-
segregation 
~4% 19 
Schizzosaccharomyces 
pombe 
Minichromosome 
loss 
~4% 139 
Drosophila melanogaster SKY ~0.1% 140-142 
Mouse fertilized eggs SKY 1-2% 143 
Human Sperm SKY  1-4% 144,145 
 FISH 1-3% 146 
Human Oocytes  SKY  10-35% 147,148 
 FISH 20-70% 147,148 
 CGH 30-75% 149,150 
Zygotes (human) FISH, SKY 5-25% 17 
Spontaneous abortions 
(human) 
SKY 35% 17,36,37 
Stillbirths (human) SKY 4% 17,36,37 
Newborns (human) SKY 0.3% 17,36,37 
Note: Plasmid, mini-chromosome and YAC loss measure mis-segregation rates; SKY, FISH and 
single cell sequencing measure incidence of aneuploidy 
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Supplementary information: Table: Mouse models of chromosomal 
instability 
 
Glossary: 
Chromothripsis: A process in which entire chromosomes are shattered and 
then stitched together in a seemingly random manner, leading to dozens 
sometimes even hundreds of rearrangements within a single chromosome.  
Dosage compensation: Alteration of mRNA or protein expression to 
compensate for variation in DNA copy number. 
Proteotoxic stress: A cellular stress elicited by unfolded/mis-folded proteins. 
Chromosomal instability (CIN): a condition in which the rate of chromosome 
mis-segregation is elevated.  
Merotelic attachment: An incorrect microtubule–kinetochore attachment where 
a kinetochore attaches to microtubules emanating from both spindle poles.  
Spectral karyotyping (SKY): A cytogenetic technique utilized to simultaneously 
visualize all chromosomes in a cell by employing different fluorescently labeled 
probes for each chromosome. 
 
Online summary: 
• Aneuploidy is defined as an abnormal karyotype that is not a multiple of 
the haploid complement. 
• Chromosome mis-segregation causes DNA damage. 
• Micronuclei form during chromosome mis-segregation. Chromosomes 
within micronuclei are underreplicated and undergo chromothripsis. 
• Chromosome mis-segregation leads to p53 activation. 
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• The complex phenotypes caused by aneuploidy are caused by changes in 
the dosage of specific genes and a generic aneuploidy-associated stress 
response.  
• Aneuploidy causes proteotoxic stress and impairs proliferation. 
• Aneuploidy is a hallmark of cancer but the relationship between 
aneuploidy and cancer is complex. Depending on the context, aneuploidy 
can promote or antagonize malignant transformation. 
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